Rovelizumab
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke[1].
Product Specifications
CAS Number
339086-79-2
Product Name Alternative
Hu23F2G
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/rovelizumab.html
Purity
97.23
Solubility
H2O
Smiles
[Rovelizumab]
Molecular Weight
(145.98 kDa)
References & Citations
[1]Jones R. Rovelizumab (ICOS Corp) . IDrugs. 2000 Apr;3 (4) :442-6. |[2]Qualls JE, et al. A double agent in cancer: stopping macrophages wounds tumors. Nat Med. 2010 Aug;16 (8) :863-4.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
